Gollob Jared

CMO Gollob sold 10,508 shares for $916.7K across 7 transactions at $87.24 blended average; stock now down -16.2% to -14.2% in 30 days post his recent KYMR sales

Jared Gollob, Chief Medical Officer, executed 7 separate sales totaling 10,508 shares for $916,668.62 across March 2–4, 2026, representing an 8.2% reduction of his 127.6K share position. The sales occurred at prices ranging from $84.00 to $89.66 per share with a blended average of $87.24, while the stock currently trades at $86.11—slightly below the transaction window. Notably, Gollob's prior five sales at KYMR (all on 2025-12-08) have all declined 12.2% to 16.2% within 30 days, establishing a consistent pattern of downside follow-through at this ticker. His cross-ticker track record shows a 22.22% well-timed sell rate (90-day negative returns) with a 10.6% average 90-day return, but his KYMR-specific history—0 of 0 prior sales well-timed at 90 days—suggests weaker predictive value in this stock. The company context is material: KYMR posted quarterly revenue of $2.8M with a net loss of $82.2M, annual revenue declined 16.7% year-over-year, and the stock is down 9.4% from its 52-week high of $95.03, raising questions about whether the CMO's exit reflects private knowledge of deteriorating fundamentals.

CMO Gollob sells 49,307 shares for $4.4M as stock hits 52-week high of $94.30

Jared Gollob, Chief Medical Officer of Kymera Therapeutics, executed 6 separate sales on 2025-12-08 totaling 49,307 shares for $4,371,832.54, reducing his holdings by 31.0% from 159,299 to 109,992 shares. The sales occurred at prices ranging from $87.37 to $92.19 (blended average $88.67), while the stock currently trades at $94.30—at its 52-week high after gaining 60.8% over 30 days and 116.9% over 90 days. The company remains unprofitable with annual revenue of $2,764,000.00 and net income of $-82,175,000.00, and reports annual revenue decline of -40.1%. Gollob's same-ticker sales history shows mixed outcomes: four October 2025 sales have shown 30-day gains (2.9% to 7.6%), while one July 2024 sale declined -0.1% over 90 days; his cross-ticker track record shows only 40.00% of prior sells were well-timed at the 90-day horizon.

Chief Medical Officer Gollob sold 59,576 shares of KYMR at $60.37–$63.09 on 2025-10-15, raising $3.7M and reducing holdings by 35.1%.

Jared Gollob (Chief Medical Officer) executed four separate sales on 2025-10-15 totaling 59,576 shares for $3,659,253.94, reducing his position from 169,568 to 109,992 shares. The sale occurred near the 52-week high (current price $62.89, 30-day change +33.0%, 90-day change +35.7%), and Kymera faces significant headwinds: annual revenue declined 40.1%, net income was negative at $-76,614,000.00, and latest quarterly revenue stood at $11,476,000.00. Against his cross-ticker track record (40.00% well-timed sell rate, avg 90d return +3.3% after prior sales), his prior trades at KYMR show only 2 of 5 sells were well-timed at the 90-day horizon, and the most recent prior KYMR sales in July 2024 yielded negative 90-day returns (-5.8%, -4.5%, -3.4%). The size (59.6K shares, -35.1% of pre-transaction holdings) and proximity to the 52-week high warrant careful attention to whether this represents reallocation or a shift in insider confidence.

CMO Jared Gollob sold 39,600 shares at $45.53 avg for $1.8M, reducing stake to 95.5K shares post-transaction

Jared Gollob, Chief Medical Officer of Kymera Therapeutics, executed 3 separate sales totaling 39,600 shares for $1,803,142.99 on July 15–16, 2024, at prices ranging from $45.15 to $46.10. This represents a -29.3% reduction in his pre-transaction holdings of 135,070 shares. The stock has since traded to $48.49, marking an all-time 52-week high (+0.0% from peak), suggesting the insider's blended sale price of $45.53 was made before the recent 45.7% 30-day rally. Gollob's prior two sales at KYMR (February 2024) both resulted in positive 90-day returns (+22.9% and +20.5%), meaning he sold before subsequent appreciation rather than before declines—a 0% well-timed rate at this ticker. The company remains unprofitable (net income -$48.6M on latest quarter revenue of $10.3M) despite strong annual revenue growth of +67.8%, which may inform the timing of this significant reduction.